Evidence map›Paper›PMID 40847237›Full record

ReviewCancer treatment and research2025

Advancing Prostate Cancer Treatment: Innovations and Challenges in Immunotherapy.

Gargi Singhal, Pankaj Garg, Atish Mohanty, Sudarsan Vishnu Kollimuttathuillam, Deric Wheeler, Bamidele A Adesunloye, Sharad S Singhal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer treatment and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. A Metastasis-competent CAF Subpopulation Defined byRecent patents on anti-cancer drug discovery · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Gargi SinghalUndergraduate Medical Sciences, S.N. Medical College Agra, Agra, Uttar Pradesh, India.
Pankaj GargDepartment of Chemistry, GLA University, Mathura, Uttar Pradesh, India.
Atish MohantyDepartment of Medical Oncology & Therapeutics Research, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA, USA.
Sudarsan Vishnu KollimuttathuillamDepartment of Medical Oncology, City of Hope, Irvine, CA, USA.
Deric WheelerDepartment of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Bamidele A AdesunloyeCity of Hope, Newnan, GA, USA.
Sharad S SinghalDepartment of Medical Oncology & Therapeutics Research, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA, USA. ssinghal@coh.org.ORCID https://orcid.org/0000-0002-6415-8160

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa), a leading cause of cancer mortality in men, has experienced a paradigm shift with the rise of immunotherapy. This chapter examines the immunological landscape of PCa and highlights key immunotherapeutic approaches, including cancer vaccines, immune checkpoint inhibitors (ICIs), adoptive cell therapies, and cytokine-based treatments. Emerging innovations, such as oncolytic viruses, neoantigen-based therapies, and bispecific antibodies, are also examined. Challenges like the immunosuppressive tumor microenvironment (TME), limited predictive biomarkers, and immune-related adverse events (irAEs) are addressed, alongside promising combination strategies with androgen deprivation therapy (ADT), radiotherapy, and targeted therapies. Advances in biomarker discovery and artificial intelligence (AI) are emphasized for their role in optimizing personalized immunotherapy. This chapter underscores the need for equitable access to these advancements and concludes with a vision for integrating immunotherapy into standard care, offering durable and transformative outcomes for PCa patients.

Indexed as

ImmunotherapyProstatic NeoplasmsCancer VaccinesHumansMaleTumor MicroenvironmentCancer VaccinesAndrogen deprivation therapyCancer vaccineChemotherapyImmune checkpoint inhibitorsImmunotherapyProstate cancerTargeted therapyTumor microenvironment

Identifiers

PMID40847237

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.